The purpose of the this study is to evaluate the efficacy and safety of 2 actuations
Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5
μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination